238 related articles for article (PubMed ID: 17851225)
21. Hsp27 may allow prediction of the response to single-agent vinorelbine chemotherapy in non-small cell lung cancer.
Berrieman HK; Cawkwell L; O'Kane SL; Smith L; Lind MJ
Oncol Rep; 2006 Jan; 15(1):283-6. PubMed ID: 16328069
[TBL] [Abstract][Full Text] [Related]
22. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
[TBL] [Abstract][Full Text] [Related]
23. Adjuvant chemotherapy for non-small cell lung cancer: a New Zealand perspective.
Sasidharan R; Gibbs D; Sullivan R; Simpson A; Perez D; Christmas T; McKeage M
N Z Med J; 2006 Nov; 119(1245):U2310. PubMed ID: 17146485
[TBL] [Abstract][Full Text] [Related]
24. Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer.
Zhai R; Liu G; Zhou W; Su L; Heist RS; Lynch TJ; Wain JC; Asomaning K; Lin X; Christiani DC
Clin Cancer Res; 2008 Jan; 14(2):612-7. PubMed ID: 18223238
[TBL] [Abstract][Full Text] [Related]
25. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
[TBL] [Abstract][Full Text] [Related]
26. Genetic polymorphisms and treatment response in advanced non-small cell lung cancer.
Su D; Ma S; Liu P; Jiang Z; Lv W; Zhang Y; Deng Q; Smith S; Yu H
Lung Cancer; 2007 May; 56(2):281-8. PubMed ID: 17222938
[TBL] [Abstract][Full Text] [Related]
27. Impact of hemoglobin levels on outcomes of adjuvant chemotherapy in resected non-small cell lung cancer: the JBR.10 trial experience.
Gauthier I; Ding K; Winton T; Shepherd FA; Livingston R; Johnson DH; Rigas JR; Whitehead M; Graham B; Seymour L
Lung Cancer; 2007 Mar; 55(3):357-63. PubMed ID: 17141357
[TBL] [Abstract][Full Text] [Related]
28. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
[TBL] [Abstract][Full Text] [Related]
29. A single-nucleotide polymorphism in the MDR1 gene as a predictor of response to neoadjuvant chemotherapy in breast cancer.
George J; Dharanipragada K; Krishnamachari S; Chandrasekaran A; Sam SS; Sunder E
Clin Breast Cancer; 2009 Aug; 9(3):161-5. PubMed ID: 19661039
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer.
Wibmer T; Kropf C; Merk T; Schumann C; Hombach V; Krüger S
Lung Cancer; 2008 May; 60(2):231-9. PubMed ID: 18006111
[TBL] [Abstract][Full Text] [Related]
31. MDR1 single nucleotide polymorphism C3435T in Turkish patients with non-small-cell lung cancer.
Dogu GG; Kargi A; Turgut S; Ayada C; Taskoylu BY; Demiray G; Yaren A; Ozlu C; Temel S; Ergin A
Gene; 2012 Sep; 506(2):404-7. PubMed ID: 22766400
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of potential interaction between vinorelbine and clarithromycin.
Yano R; Tani D; Watanabe K; Tsukamoto H; Igarashi T; Nakamura T; Masada M
Ann Pharmacother; 2009 Mar; 43(3):453-8. PubMed ID: 19261952
[TBL] [Abstract][Full Text] [Related]
33. XPG is predictive gene of clinical outcome in advanced non-small-cell lung cancer with platinum drug therapy.
Zhang T; Sun J; Lv M; Zhang L; Wang X; Ren JC; Wang B
Asian Pac J Cancer Prev; 2013; 14(2):701-5. PubMed ID: 23621222
[TBL] [Abstract][Full Text] [Related]
34. Vinorelbine--a clinical review.
Gregory RK; Smith IE
Br J Cancer; 2000 Jun; 82(12):1907-13. PubMed ID: 10864196
[No Abstract] [Full Text] [Related]
35. Association of drug transporter gene ABCB1 (MDR1) 3435C to T polymorphism with colchicine response in familial Mediterranean fever.
Tufan A; Babaoglu MO; Akdogan A; Yasar U; Calguneri M; Kalyoncu U; Karadag O; Hayran M; Ertenli AI; Bozkurt A; Kiraz S
J Rheumatol; 2007 Jul; 34(7):1540-4. PubMed ID: 17610314
[TBL] [Abstract][Full Text] [Related]
36. Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC).
Tsoutsou PG; Froudarakis ME; Bouros D; Koukourakis MI
Anticancer Res; 2008; 28(2B):1349-54. PubMed ID: 18505077
[TBL] [Abstract][Full Text] [Related]
37. A meta-analytic review of ERCC1/MDR1 polymorphism and chemosensitivity to platinum in patients with advanced non-small cell lung cancer.
Wei HB; Hu J; Shang LH; Zhang YY; Lu FF; Wei M; Yu Y
Chin Med J (Engl); 2012 Aug; 125(16):2902-7. PubMed ID: 22932088
[TBL] [Abstract][Full Text] [Related]
38. [Vinorelbine for non-small cell lung cancer].
Seto T
Nihon Rinsho; 2002 May; 60 Suppl 5():353-8. PubMed ID: 12101688
[No Abstract] [Full Text] [Related]
39. Multidrug resistance 1 genotype and disposition of budesonide in early primary biliary cirrhosis.
Dilger K; Cascorbi I; Grünhage F; Hohenester S; Sauerbruch T; Beuers U
Liver Int; 2006 Apr; 26(3):285-90. PubMed ID: 16584389
[TBL] [Abstract][Full Text] [Related]
40. Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients.
Xu X; Ren H; Zhou B; Zhao Y; Yuan R; Ma R; Zhou H; Liu Z
Lung Cancer; 2012 Aug; 77(2):438-42. PubMed ID: 22516052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
